Wire · opportunities
Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 October 2026 · Fusion42 review
Editas Medicine received approval from Australian regulators to begin a Phase 1/2 clinical trial of its gene editing therapy EDIT-401 for patients with familial hypercholesterolemia, with plans to start dosing this year and report early data in 2027. The therapy aims to reduce LDL cholesterol by editing the LDLR gene, showing promising preclinical durability results.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Gene therapy founders developing treatments for genetic lipid disorders gain a clear regulatory pathway in Australia that could accelerate patient access and trial momentum. You can now prepare to engage early with trial sites and anticipate initial clinical signals in the next year.
◆ Coverage
1 source · 8 Oct 2026
◆ Related on Wire
◆ Topics